WSTAM
BIB icon

Wilbanks Smith & Thomas Asset Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,330
Closed -$231K – 340
2017
Q2 		$231K Buy
+4,330
New +$211K 0.02% 282
2015
Q4 		– Sell
-8,140
Closed -$474K – 282
2015
Q3 		$474K Buy
+8,140
New +$694K 0.07% 151

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's BIB Position: Q3 2017 in Review

Wilbanks Smith & Thomas Asset Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2017, closing a stake of 4,330 shares — an estimated $231K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in BIB in Q3 2015 and held it in 2 quarters. The position peaked at $474K in Q3 2015. 33 funds tracked by Wall St. Rank hold BIB as of Q3 2017.

  • Wilbanks Smith & Thomas Asset Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2017 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 4,330 ProShares Ultra NASDAQ Biotechnology shares in Q3 2017, an estimated $231K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2015 and held it in 2 quarters.
  • Wilbanks Smith & Thomas Asset Management's ProShares Ultra NASDAQ Biotechnology position peaked at $474K in Q3 2015.
  • 33 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2017.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.